Uncategorized
Thermo Fisher sees higher Q1 earnings amid strong biopharma demand
Thermo Fisher Scientific reported “a strong start to the year,” buoyed by strong demand from its pharma and biotech customers, investment in new technologies and the closing of its $9 billion acquisition of clinical trial data company Clario.